c-Met is a receptor tyrosine kinase (RtK) with a critical role in many fundamental cellular processes, including cell proliferation and differentiation. Deregulated c-Met signaling has been implicated in both the initiation and progression of human cancers and therefore represents an attractive target for anticancer therapy. Monitoring the phosphorylation status of relevant tyrosine residues provides an important method of assessing c-Met kinase activity. this report describes a novel assay to monitor c-Met phosphorylation in cells using Amplified Luminescent proximity homogeneous Assay (AlphaScreen) technology. Using AlphaScreen, the authors were able to detect both global and site-specific phosphorylation of c-Met in transformed cell lines. Data obtained from the AlphaScreen assay were compared to data obtained from a high-content imaging (hcI) method developed in parallel to monitor c-Met phosphorylation at the single cell level. the AlphaScreen assay was miniaturized to a 384-well format with acceptable signal-to-background ratio (S/B) and Z′ statistics and was employed to measure c-Met kinase activity in situ after treatment with potent c-Met-specific kinase inhibitors. the authors discuss the utility of quantifying endogenous cellular c-Met phosphorylation in lead optimization and how the modular design of the AlphaScreen assay allows its adaptation to measure cellular activity of other kinases. (Journal of Biomolecular Screening 2009:404-411) 
INTRODUCTION
A S A ReceptOR fOR hepAtOcyte gROwth fActOR (hgf), 1, 2 c-Met 3-5 regulates cell proliferation, survival, and migration. [6] [7] [8] Deregulated c-Met stimulates growth in transformed cells, and c-Met has been shown to be mutated and/or overexpressed in many solid tumors. 9,10 therefore, c-Met is an increasingly attractive target for oncology drug development. [11] [12] [13] [14] c-Met, like most prototypical receptor tyrosine kinases (RtKs), exists as an α 2 -β 2 heterodimer. the extracellular α-subunits confer on c-Met the ability to bind hgf with high affinity. the β-subunit is an integral membrane protein with a single transmembrane domain. the majority of the c-Met β-subunit is intracellular and contains the catalytic tyrosine kinase domain. the αand β-subunits are linked by disulfide bonds. hgf binding to c-Met induces a conformational change that promotes activation of the intracellular kinase domain, receptor autophosphorylation, and subsequent recruitment of critical downstream signaling factors 15, 16 that culminates in an array of biological events, including invasion, progression, and metastasis of transformed cells. More specifically, autophosphorylation of tyrosines 1230, 1234, and 1235 (y1230/y1234/y1235) located within the activation loop of the c-Met tyrosine kinase domain is crucial for activation of c-Met tyrosine kinase activity, whereas y1349 autophosphorylation activates the multisubstrate signal transducer docking site. 13, 15, 17, 18 Upon autophosphorylation, these tyrosines bind and activate multiple signal transducers, including the grb2/SOS complex, pI 3-kinase, and phospholipase-c (pLc-y). 5, 13, 18, 19 given the crucial role c-Met plays in neoplastic transformation and its well-characterized RtK activity, assays that monitor c-Met phosphorylation status should serve as important biomarker assays for neoplastic development. [20] [21] [22] traditionally, receptor phosphorylation has been measured in cells using immunobased methods, including enzyme-linked immunosorbent assays (eLISAs) 23 or western blotting. 24 Despite their sensitivity and specificity, these methods are not readily compatible with lead optimization or ultra-highthroughput screening (uhtS) as they are of low throughput, laborious, and time-consuming. It is therefore advantageous to develop assays comparable in sensitivity to these traditional methods but with the speed and flexibility required for lead optimization and uhtS. In our study, we have implemented AlphaScreen for the investigation of bimolecular interactions in microplate format. [25] [26] [27] [28] [29] AlphaScreen is a sensitive, beadbased technology, ideally suited for uhtS because it is nonradioactive, does not require separation or washing steps, and can be easily automated and miniaturized.
to develop a novel cell-based AlphaScreen c-Met phosphorylation assay, we took advantage of the availability of a pan-phosphotyrosine antibody py20 as well as antibodies directed against specific c-Met autophosphorylation sites, including py1230/py1234/py1235 and py1349 ( Fig. 1) . 24 we chose to measure c-Met phosphorylation in the human gastric tumor cell line gtL-16 as these cells have been shown to possess constitutively high c-Met protein kinase activity. 5, 30, 31 the same py20, py1230/py1234/py1235, and py1349 antibodies were used to monitor c-Met tyrosine phosphorylation in a high-content imaging (hcI) assay using the Molecular Devices (Blueshift) Isocyte instrument. All these assays were performed with acceptable signal-to-background ratios and Z′ statistics and were used to determine the potency of both pan-kinase and specific c-Met inhibitors.
MATeRIAlS AND MeTHODS

Reagents and materials
human gastric carcinoma gtL-16 cells, a derivative of the MKN45 cell line, were a gift from S. giordano and p. M. comoglio (University of torino Medical School, candiolo, Italy). Biotinylated antihuman hgfR (anti-c-Met) antibody was purchased from R&D Systems (Minneapolis, MN, cat. BAf358). Anti-py1230/py1234/py1235 and anti-py1349 were purchased from Abcam, Inc. (cambridge, MA, cat. ab5662 and cat. ab47606). py20 detection kit (cat. 6760601) and protein A detection kit (cat. 6760617) were purchased from perkinelmer (waltham, MA).
Cell culture
gtL-16 cells were grown in RpMI 1640 media supplemented with 10% fetal bovine serum (fBS; hyclone, Logan, Ut, cat. Sh30070) at 37 °c and 5% cO 2 . when cells reached 95% confluence, they were harvested, washed, and resuspended in RMpI 1640 media (gibco, carlsbad, cA, cat. 11835030) without phenol red and supplemented with 10% fBS for plating. cell viability was determined using trypan blue dye exclusion, and cells were seeded at 5 × 105 viable cells/mL, 20 µl/well, in 384well white Optiplate microplates (perkinelmer, cat. 6007299) for the AlphaScreen assay. for hcI assays, cells were plated in black, clear-bottom 96-well plates coated with poly-D-lysine (BD Biosciences, San Jose, cA, cat. 354640) at 1 × 105 cells/ mL, 100 µL/well. hcI assay was also performed in a 384-well format using 0.5 × 105 cell/mL, 50 µL/well.
Compound treatment
where indicated for both the AlphaScreen and hcI assays, staurosporine or Merck compounds were prepared as stock solutions in 100% DMSO. compounds were further diluted in RMpI 1640 media (gibco, cat. 11835030) without phenol red to the desired concentrations and then added directly to the cells. final DMSO concentration reached in all experiments was 0.3%.
Detection of c-Met pY20, pY1230/pY1234/pY1235, pY1349 phosphorylation by AlphaScreen TM assay
the assay scheme is depicted in Figure 1 . After an overnight incubation at 37 °c, all media were removed from the assay plate and replaced with 10 µL/well of compound (or DMSO only) diluted in RpMI media without phenol red and without fBS. plates were then incubated for 30 min at 37 °c. to monitor global c-Met phosphorylation, we lysed cells by the addition of 5 µL lysis buffer to each well. the final optimized lysis buffer contained 30 mM tris-hcl (ph 7.5), 5 mM eDtA, 50 mM Nacl, 30 mM Nappi, 50 mM Naf, 0.5% (vol/vol) IgepAL cA-630, 1% (vol/vol) triton X-100, 10% glycerol, Roche Mini-complete (without eDtA) protease inhibitor cocktail, 0.1 mg/mL potassium bisperoxo (1,10-phenanthroline) oxovanadate (bpVphen), 1% (vol/vol) phenylmethylsulfonyl fluoride (pMSf), and 0.5 mg/mL Microcystin-LR. After 20 min at room temperature, 5 µL of anti-c-Met (antireceptor) antibody was added to each well to reach a final concentration of 1 µg/mL, and plates were allowed to incubate for an additional 60 min at room temperature. A mixture of anti-py20 acceptor and streptavidin-coated donor beads was added into each well of the assay plate and incubated at room temperature for an additional 60 min. the plates were read on an enVision multilabel plate reader (perkinelmer) using the AlphaScreen protocol. for py1230/py1234/py1235 and py1349 detection, the procedure was identical except that the site-specific phospho-antibodies noted above and protein A acceptor beads were used instead of py20-coated acceptor beads. Specificity of phospho-antibodies was confirmed by western blot (data not shown).
Detection of c-Met pY20, pY1230/pY1234/pY1235, pY1349 phosphorylation using an HCI assay
After the compound treatment procedure described above, cells were fixed with the cytofix/cytoperm kit (Becton-Dickinson, franklin Lakes, NJ, cat. 554714) and treated with the indicated antiphosphotyrosine antibodies at a final concentration of 5 µg/mL. following a 60-min incubation at room temperature, 10 µg/mL of fItc-conjugated antirabbit Igg (Abcam) was added as a secondary antibody for detection of the primary antiphosphotyrosine antibodies. ethidium homodimer-1 was added to stain the nuclei at a 1-µg/mL final concentration. After a 60-min incubation at room temperature and 3 washes with 1× phosphate-buffered saline (pBS) using a Biotek eLx405 microplate washer, the plate was imaged on a Blueshift Biotechnologies (Sunnyvale, cA) Isocyte instrument. fItc (green) fluorescence emission was filtered through a 510-to 540-nm bandpass filter for channel 1 (ch1), and ethidium homodimer-1 fluorescence emission (red) was filtered through a 600-nm-long pass filter for channel 3 (ch3).
DATA ANAlySIS
AlphaScreen TM assay to monitor assay sensitivity and robustness, we calculated signal-to-background (S/B) ratio and Z′ parameters. 32 All dose-response curves were plotted using calculated percent inhibition versus inhibitor concentration. percent inhibition was calculated as Ic 50 values for inhibitors were determined using 4-parameter curve fitting by graphpad prism v4 (graphpad Software, San Diego, cA).
HCI assays
wells were scanned at a 5-micron resolution using the Isocyte tM 488-nm argon laser. the ethidium homodimer-1 nuclear counterstain (Invitrogen, carlsbad, cA, cat. e1169) was used to identify individual cells as contiguous areas brighter than background fluorescence in channel 3 (red) using BlueImage cell analysis software (Blueshift Biotechnologies) and allowed to set up a threshold calculated based on max and min for intensity values of objects in channel 3. channel 1 (green) signal was then measured only in areas defined as a cell. this channel 1 (fItc) signal was integrated across all cells in the well to determine total cell fluorescence per well. A normalized fluorescence/cell was determined by taking the ratio of integrated channel 1 fluorescence per well to the number of cells per well as the following: fluorescence per cell = (mean fluorescence intensity ch1 -mean background)/number of cells.
curve fitting and the Ic 50 value for staurosporine were determined using graphpad prism v4.
ReSUlTS AND DISCUSSION
to maximize the recovery of intact phosphorylated c-Met and reduce potential interference from cell and media components, 33 we initiated AlphaScreen assay development with optimization of cell lysis conditions. this optimization, along with optimization of detection reagents, was particularly important for this assay because the assay was intended to be modular in nature such that the same lysis and detection conditions could be used with different antibodies for detection of global and site-specific c-Met phosphorylation. Initial conditions for cell lysis employed lysis buffer 1, which consisted of 30 mM tris-hcl (ph 7.5), 5 mM eDtA, 50 mM Nacl, 10% glycerol (vol/vol), and 1% triton X-100 (vol/vol). these conditions resulted in a low S/B ratio (<2.5) and high variability, resulting in negative Z′ values for experiments using this buffer (Fig. 2) . further optimization experiments were performed with lysis buffer 2, which, along with the components of lysis buffer 1, contained protease inhibitors (pMSf and Roche Mini-complete protease inhibitor cocktail with additional phosphatase inhibitors [30 mM Nappi, 50 mM Naf]). Lysis buffer 2 did improve the S/B ratio to 6, but the resulting Z′ was <0.3, indicating that assay robustness was still unacceptable for compound screening (Fig. 2) . further improvements in both S/B and Z′ were obtained by adding the nonionic detergent IgepAL cA-630 and the additional protein phosphatase inhibitors Microcystin-LR and bpV-phen to produce lysis buffer 3. Using lysis buffer 3, the S/B ratio and Z′ improved to 17 and 0.7, respectively. Results from buffer optimization experiments include the observation that the simplest assay buffer (lysis buffer 1) did not perform adequately, even yielding a negative Z′. Significant increases in assay performance (both signal/background and variability) were achieved by the addition of nonionic detergent, protease inhibitors, and phosphatase inhibitors. Indeed, all 3 additions were required to achieve maximal detection of phosphorylated c-Met from cells. Because the best assay performance was achieved using lysis buffer 3, further assay development was performed using this buffer.
Optimization of binding partner concentrations in a homogeneous assay is critical as excess of such assay components can result in competition between saturated bound and unbound molecules, which can significantly decrease signal and/or increase assay background. Optimization of binding partner concentrations for the c-Met AlphaScreen assay required optimization of cell number and detection reagent concentrations. to accomplish this, we titrated cells against varying concentrations of anti-c-Met antibody. Streptavidin donor and py20 acceptor (for detection of global tyrosine phosphorylation) bead concentrations were kept constant. Upon cell number and antibody titration, we observed an antibody concentration-dependent increase in signal at each cell density used. considering the data, the optimal cell density and anti-c-Met (antireceptor) antibody concentration were determined to be 1 × 10 4 cells/well and 1 µg/mL anti-c-Met antibody (Fig. 3) . these values for cell number and anti-c-Met antibody concentration were used in subsequent experiments to optimize donor and acceptor bead concentrations. for these experiments, different amounts of AlphaScreen beads were diluted in pBS containing 0.1% bovine serum albumin (BSA) and added to assay wells to test different final concentrations and ratios of donor and acceptor beads. A maximal S/B of 24 and Z′ of 0.8 were observed when donor and acceptor beads were used in the assay at final concentrations of 15 µg/mL and 45 µg/mL, respectively ( Table 1) . these optimized conditions for cell lysis and detection of global c-Met phosphorylation were subsequently used to measure site-specific phosphorylation of c-Met. these experiments were designed to test whether this c-Met Alpha-Screen assay was indeed modular in nature, allowing the facile substitution of phosphotyrosine antibodies without a complex reoptimization of all assay conditions. to measure phosphorylation of specific c-Met tyrosine residues, we tested antibodies directed against 2 autophosphorylation sites (c-Met tyrosines 1230/1234/1235 and 1349) under the assay conditions described above for the detection of global c-Met tyrosine phosphorylation. titration of anti-py1230/py1234/ the effects of varying concentrations of AlphaScreen donor and acceptor beads were determined using previously optimized cell lysis conditions, cell density, and antibody concentrations (Figs. 2, 3) . Although signal to background (S/B) and Z′ were acceptable using donor and acceptor beads in the range of 15 to 45 µg/mL, higher concentrations of donor beads reduced the signal-to-background ratio. the use of 15-µg/mL donor and 45-µg/mL acceptor bead concentrations resulted in the best S/B and Z′ values and were 24 and 0.8, respectively.
py1235 and anti-py1349 antibodies was first conducted to determine the optimal antibody concentration using S/B and Z′ as measures of assay performance ( Table 2) . for the anti-py1230/ py1234/py1235 antibody, the optimal concentration was 10 µg/mL Ab, producing an S/B ratio of 13 and a Z′ of 0.6. the optimal concentration for the anti-py1349 antibody was 5 µg/mL Ab, producing an S/B ratio of 19 and a Z′ of 0.8. these results were consistent with the desired modular nature of this c-Met AlphaScreen assay: acceptable assay performance was achieved with only the optimization of detection antibody concentrations.
Reoptimization of other assay conditions was not required to achieve assay statistics compatible with high-throughput screening. the ability of the AlphaScreen assay to monitor effects of known c-Met inhibitors on global and site-specific c-Met phosphorylation was also tested. for these experiments, gtL-16 cells were treated with increasing concentrations of either the pan-kinase inhibitor staurosporine or with 2 c-Met-selective kinase inhibitors (Merck compounds A and B). As shown in Figure 4 , exposing the cells to increasing concentrations of each inhibitor resulted in a concentration-dependent inhibition of global c-Met tyrosine phosphorylation (py20) and of c-Met sitespecific autophosphorylation (py1230/py1234/py1235, py1349). Interestingly, all the inhibitors demonstrated a similar rank order of potency regardless of whether global or site-specific inhibition of c-Met tyrosine phosphorylation was measured. the rank order Ic 50 potency across phosphorylation sites was py20 ≈ py1349 < py1230/py1234/py1235 (Fig. 4, Ic 50 values in legend).
HCI analysis of global and specific tyrosine phosphorylation sites
to verify our data from the AlphaScreen assay, we used an hcI method employing the laser-scanning Isocyte instrument to measure phosphorylation of c-Met in situ. gtL-16 cells were treated with increasing concentrations of staurosporine, and both global and site-specific c-Met phosphorylation were determined (algorithms detailed in Materials and Methods). Staurosporine treatment displayed concentration-dependent inhibition of tyrosine phosphorylation as detected by global (py20) and sitespecific (py1230/py1234/py1235, py1349) antibodies (Fig.  5A) . the decrease in signal intensity was not due to cell loss induced by exposure to staurosporine as the total mean intensity obtained for the ethidium homodimer nuclear stain (channel 3, red emission) did not change significantly at any of the concentrations tested (Fig. 5B) . Representative images obtained with the Isocyte are shown to demonstrate the effect of challenging gtL-16 cells with increasing concentrations of staurosporine on the magnitude of global tyrosine phosphorylation via py20 staining. when the data obtained from this hcI assay are compared with results obtained from the AlphaScreen assay, staurosporine elicits similar results for calculated Ic 50 values, and rank order potency is preserved (i.e., py20 ≈ py1349 < py1230/py1234/py1235). Results obtained using the Isocyte were also similar to results obtained using automated microscopy (ge/Amersham Biosciences, Incell 1000) rather than laser scanning (data not shown). 
The role of a c-Met AlphaScreen TM in the kinase assay toolbox
this study illustrates the development of an AlphaScreen assay to monitor global and site-specific autophosphorylation of the receptor tyrosine kinase c-Met. compound potency data obtained by testing the effects of staurosporine and 2 in-house Merck compounds on c-Met phosphorylation clearly demonstrate the utility of this assay as a potential screening tool for the characterization of c-Met inhibitors. Data obtained in hcI assays confirmed data obtained in the AlphaScreen assay, providing even greater confidence in employing the AlphaScreen assay for screening c-Met kinase inhibitors. to achieve a robust AlphaScreen assay for c-Met (miniaturized in these studies to FIG. 4. Determination of c-Met inhibitor potency using optimized AlphaScreen assay. the pan-kinase inhibitor staurosporine and 2 internal Merck c-Met inhibitors were administered to cells at concentrations increasing from 0.2 nM to 10 µM. Site-specific c-Met phosphorylation was assayed using py1349 and py1230/py1234/py1235 antibodies, and global c-Met phosphorylation was assayed using the py20 antibody. with both Merck inhibitors, similar potencies were obtained using all 3 antibodies with slightly lower potencies for both inhibitors obtained using py1349. this difference was not seen with staurosporine. a 384-well format), we optimized multiple factors. Optimization of cell lysis conditions was found to be a critical component of assay development, whereby nonionic detergents, protease inhibitors, and phosphatase inhibitors all improved the preservation of intact phosphorylated c-Met from cells, as displayed in increases in the assay statistics of S/B and Z′. the AlphaScreen assay developed for c-Met was intentionally modular in design: AlphaScreen donor beads in all assays were streptavidin coated to bind biotinylated anti-c-Met antibody and thus capable of capturing c-Met from cell lysates. AlphaScreen protein A acceptor beads could then be used with one of several FIG. 5. Validation of AlphaScreen c-Met assay using a high-content imaging (hcI) assay. An hcI assay employing the laser-scanning Isocyte instrument was used to measure the effect of staurosporine on both site-specific and global tyrosine phosphorylation of c-Met. Intensity of signal from each antibody was used to determine staurosporine potency: (A) dose-response curves in (B) 96-well format. effect of 2 Merck compounds and staurosporine was also measured using py20 antibody in a 384-well format on Isocyte: (C) dose-response curves.
antibodies capable of detecting site-specific or global c-Met phosphorylation sites. cell lysis and detection reagent optimization conditions were robust for all antibodies used, simplifying assay development and serving as a model for a kinase assay design that allows the tracking of multiple different phosphorylation sites without complex assay reconfiguration for each new site to be monitored (and each new antibody employed in the assay). this ability to rapidly monitor site-specific phosphorylation can greatly enhance the lead optimization for new-generation kinase inhibitors that require enhanced specificity and selectivity in their mechanisms of action.
